Chorea News and Research

RSS
SATI gene editing could replace CRISPR

SATI gene editing could replace CRISPR

Researchers identify crucial player in controlling misfolded proteins

Researchers identify crucial player in controlling misfolded proteins

Sleep disorders appear to be first sign of serious neurological diseases

Sleep disorders appear to be first sign of serious neurological diseases

New test methods with less fear

New test methods with less fear

Newly discovered molecular chaperones may soon be part of therapies for Huntington's disease

Newly discovered molecular chaperones may soon be part of therapies for Huntington's disease

Dendritic-specific Golgi plays key role in early neuropathy of degenerative brain disease

Dendritic-specific Golgi plays key role in early neuropathy of degenerative brain disease

Research reveals new molecular mechanisms of Huntington's disease

Research reveals new molecular mechanisms of Huntington's disease

Computer-adaptive tests to measure health-related quality of life in Huntington's disease patients

Computer-adaptive tests to measure health-related quality of life in Huntington's disease patients

New biomarker test helps detect autoimmune-induced neuropsychiatric disorders

New biomarker test helps detect autoimmune-induced neuropsychiatric disorders

Deutetrabenazine may help improve chorea symptoms in patients with HD

Deutetrabenazine may help improve chorea symptoms in patients with HD

Deuteration offers alternative chorea treatment for Huntington disease patients

Deuteration offers alternative chorea treatment for Huntington disease patients

Diseases that cause skin-related problems can also trigger serious neurological conditions

Diseases that cause skin-related problems can also trigger serious neurological conditions

Neurocrine Biosciences announces positive data from NBI-98854 Phase III trial in tardive dyskinesia

Neurocrine Biosciences announces positive data from NBI-98854 Phase III trial in tardive dyskinesia

Neurocrine completes enrollment in Phase III clinical trial of NBI-98854 in tardive dyskinesia patients

Neurocrine completes enrollment in Phase III clinical trial of NBI-98854 in tardive dyskinesia patients

Ruhr-Universität Bochum scientists develop mouse model to investigate SCA6

Ruhr-Universität Bochum scientists develop mouse model to investigate SCA6

Neurocrine reports net loss of $1.2 million for first quarter 2015

Neurocrine reports net loss of $1.2 million for first quarter 2015

Neurocrine Biosciences, Mitsubishi Tanabe to develop and commercialize NBI-98854 in select Asian markets

Neurocrine Biosciences, Mitsubishi Tanabe to develop and commercialize NBI-98854 in select Asian markets

Neurocrine Biosciences' NBI-98854 drug gets breakthrough designation for tardive dyskinesia

Neurocrine Biosciences' NBI-98854 drug gets breakthrough designation for tardive dyskinesia

Cedars-Sinai experts to present free conference on dystonia for patients, families and caregivers

Cedars-Sinai experts to present free conference on dystonia for patients, families and caregivers

Auspex enrolls first patient in SD-809 Phase 3 trial for treatment of chorea associated with HD

Auspex enrolls first patient in SD-809 Phase 3 trial for treatment of chorea associated with HD